Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population

References

• Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–1769.
   PubMed Web of Science ®Google Scholar
• Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–1227.
   PubMed Web of Science ®Google Scholar
• Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4(1):87–93.
   PubMed Web of Science ®Google Scholar
• Savage P, Waxman J. Post-transplantation lymphoproliferative disease. Qjm. 1997;90(8):497–503.
   PubMedGoogle Scholar
• Penn I. Immunosuppression: a contributory factor in lymphoma formation. Clin Transplant 1992;6:214–219.
   Google Scholar
• Portell C, Nand S. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder. Blood. 2008;111(8):4416–4417.
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233–1243.
   PubMed Web of Science ®Google Scholar
• Kalra A, Roessner C, Jupp J, et al. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Clin Transplant. 2018;32(1):e13150.
   Web of Science ®Google Scholar
• Ali H, Soliman KM, Shaheen I, et al. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis. Int Urol Nephrol. 2020;52(4):791–802. DOI:https://doi.org/10.1007/s11255-020-02418-w.
   PubMed Web of Science ®Google Scholar
• Styczynski J, on behalf of the Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organizat, van der Velden W, Fox CP, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. JASN. 2005;16(6):1758–1774.
   Web of Science ®Google Scholar
• Nijland ML, Kersten MJ, Pals ST, et al. Ten Berge IJM. Epstein-Barr Virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplantation Direct. 2016;2(1):e48–e.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Lymphoma Action | Post-transplant lymphoproliferative disorder (PTLD) [Internet]. Lymphoma Action. 2020. [cited 1 Mar 2020]. Available from: https://lymphoma-action.org.uk/types-lymphoma-lymphoma-and-other-conditions/post-transplant-lymphoproliferative-disorder-ptld.
   Google Scholar
• Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574–1583. DOI:https://doi.org/10.1016/j.mayocp.2015.07.005.
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215–222.
   PubMed Web of Science ®Google Scholar
• Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66(12):1770–1779.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 1991;10(6):877.
   PubMed Web of Science ®Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–1088.
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86(9):3333–3340.
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J. 2015;8(5):637–644.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant. 2005;5(4p2):874–886.
   PubMedGoogle Scholar
• Meier-Kriesche H-U, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6(5p2):1111–1131.
   PubMedGoogle Scholar
• Markmann JF, Fishman JA. Alemtuzumab in kidneytransplant recipients. N Engl J Med. 2011;364(20):1968–1969.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR. Post-transplant lymphoproliferative disease: association with induction therapy? Drugs. 2006;66(4):429–438.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Tejani AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2(10):993–998.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001; 71:1065–1068.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant. 2005;9(5):622–626.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7(11):2619–2625.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis. 2011;58(6):971–980.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438.
   PubMed Web of Science ®Google Scholar
• Caillard S, for the French Transplant Centers, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant. 2012;12(3):682–693.
   PubMed Web of Science ®Google Scholar
• Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76(9):1289–1293.
   PubMed Web of Science ®Google Scholar
• Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005;80(2):193–197.
   PubMed Web of Science ®Google Scholar
• Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol. 2011;86(2):206–209.
   PubMed Web of Science ®Google Scholar
• Choi JH, Park BB, Suh C, et al. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci. 2010;25(4):523–526.
   PubMed Web of Science ®Google Scholar